Low molecular weight heparin reduces triglyceride, VLDL and Cholesterol/HDL levels in hyperlipidemic diabetic patients on hemodialysis

American Journal of Nephrology

Volumn 18, Issue 5, 1998, Pages 384-390

  Yang, Chih Wei ^a   Wu, Tsung Han ^a   Huang, Chiu Ching ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Diabetes mellitus; Hemodialysis; Hyperlipidemia; Low molecular weight heparin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HEMOGLOBIN A1C; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ANTICOAGULATION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTICOAGULANTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, VLDL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HEPARIN; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; NADROPARIN; RENAL DIALYSIS; TRIGLYCERIDES;

EID: 0031663813     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000013381     Document Type: Article

References (21)

1. Appel G: Lipid abnormalities in renal disease. Kidney Int 1991;39:169-183.
2. Ma KW, Greene EL, Raij L: Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis 1992; 19:505-513.
3. Tschope W, Koch M, Thomas B, et al: Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabetes and Uremia. Nephron 1993;64:354-358.
4. Parfrey PS: Cardiac and cerebrovascular disease in chronic uremia. Am J Kidney Dis 1993: 21:77-80.
5. Weintraub M, Rassin T, Eisenberg S, et al: Continuous intravenous heparin administration in humans causes a decrease in serum Iipolytic activity and accumulation of chylomicrons in circulation. J Lipid Res 1994;35:229-238.
6. Schrader J, Stibbe W, Armstrong VW, et al: Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988;33:890-896.
7. Deuber HJ, Schulz W: Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int 1991;40: 496-500.
8. Schmitt Y, Schneider H: Low-molecular-weight heparin (LMWH): Influence on blood lipids in patients on chronic haemodialysis. Nephrol Dial Transplant 1993;8:438-442.
9. Kronenberg F, Konig P, Neyer U, et al: Influence of various heparin preparations on lipoproteins in hemodialysis patients: A multi-center study. Thromb Haemost 1995;74:1025-1028.
10. Kronenberg F, Konig P, Lhotta K, et al: Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients. Clin Nephrol 1995;43:399-404.
11. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
12. Huang CC: Dialysis therapy in Taiwan - 1995. J Nephrol ROC 1996,9:71-83.
13. Kronenberg F, Kathrein H, Konig P, et al: Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 1994; 14:1405-1411.
14. Dieplinger H, Lackner C, Kronenberg F, et al: Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 1993;91:397-401.
15. Warkentin TE, Levine MN, Hirsh J, et al: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractinated heparin. N Engl J Med 1995; 332:1330-1335.
16. Jagroop IAB: A low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombin-induced platelet shape change and does not enhance spontaneous platelet aggregation. Br J Clin Pharmacol 1996;41:163-165.
17. Kaysen GA: Hyperlipidemia of chronic renal failure. Blood Purif 1994;12:60-67.
18. Attman PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993;21:573-592.
19. Arnadottir M, Thysell H, Dallongeville J, et al: Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int 1995;48:779-784.
20. Akiba T, Tachibana K, Ozawa K, et al: Long-term use of low molecular weight heparin ameliorates hyperlipidemia in patients on hemodialysis. ASAIO J 1992;38:M326-M330.
21. .Arnadottir M, Kurkus J, Nilsson-Ehle P: Different types of heparin in haemodialysis: Long-term effects on post-hepann lipases. Scand J Clin Lab Invest 1994;54:515-521.